
Shares of Clearmind Medicine Inc. (NASDAQ:CMND) are falling Friday after the clinical-stage biotech company shared a key update about its stock listing.
What To Know: Clearmind said it received a Nasdaq delisting notification last week. Nasdaq requires companies to maintain a minimum of $2.5 million in stockholders’ equity. However, on a Form 6-K that Clearmind filed in September, it reported a stockholders’ equity of $1,065,668.